MLYS

SEC source: 0001933414-26-000121 · wk-form4_1790978009.xml · nonDerivative · entry 1

Congleton Jon · CIK 0001644975 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 528,621

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2025.

F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $25.0000 to $25.8201. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001963901-26-000003 · wk-form4_1790300978.xml · nonDerivative · entry 1

Slingsby Brian Taylor · CIK 0001963901 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 7,805,718

F1 · kind: Represents shares of common stock sold by Catalys Pacific Fund, LP. See footnote (3).

F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $28.700 to $28.905. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.nature: Represents shares of common stock held of record by Catalys Pacific Fund, LP. Catalys Pacific Fund GP, LP is the general partner of Catalys Pacific Fund, LP. Catalys Pacific, LLC is the general partner of Catalys Pacific Fund GP, LP, and Mr. Slingsby is the managing partner of Catalys Pacific, LLC. Accordingly, Mr. Slingsby may be deemed to share voting and investment power over the shares held of record by Catalys Pacific Fund, LP. Mr. Slingsby disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.

SEC source: 0001916048-26-000014 · wk-form4_1790117313.xml · derivative · entry 3

Warren Eric · CIK 0001916048 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 230,563

Underlying: Common Stock · 7,438 shares

Expires 2035-04-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 stock selling plan adopted on March 27, 2026.

F3 · derivative.exercise_date: The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter.

SEC source: 0001916048-26-000014 · wk-form4_1790117313.xml · nonDerivative · entry 2

Warren Eric · CIK 0001916048 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 38,400

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 stock selling plan adopted on March 27, 2026.

F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $27.94 to $28.21. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

SEC source: 0001916048-26-000014 · wk-form4_1790117313.xml · nonDerivative · entry 1

Warren Eric · CIK 0001916048 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 45,838

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 stock selling plan adopted on March 27, 2026.

SEC source: 0001816952-26-000005 · wk-form4_1789681270.xml · derivative · entry 3

Karydas Daphne · CIK 0001816952 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Common Stock · 3,000 shares

Expires 2033-09-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 22, 2025.

F2 · derivative.exercise_date: The stock option vests in 36 monthly installments beginning on October 13, 2023.

SEC source: 0001816952-26-000005 · wk-form4_1789681270.xml · nonDerivative · entry 2

Karydas Daphne · CIK 0001816952 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,200

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 22, 2025.

SEC source: 0001816952-26-000005 · wk-form4_1789681270.xml · nonDerivative · entry 1

Karydas Daphne · CIK 0001816952 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 9,200

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 22, 2025.

SEC source: 0001916048-26-000012 · wk-form4_1787692603.xml · derivative · entry 3

Warren Eric · CIK 0001916048 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 238,001

Underlying: Common Stock · 7,437 shares

Expires 2035-04-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 stock selling plan adopted on March 27, 2026.

F3 · derivative.exercise_date: The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter.

SEC source: 0001916048-26-000012 · wk-form4_1787692603.xml · nonDerivative · entry 2

Warren Eric · CIK 0001916048 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 38,400

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 stock selling plan adopted on March 27, 2026.

F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $25.82 to $26.15. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

SEC source: 0001916048-26-000012 · wk-form4_1787692603.xml · nonDerivative · entry 1

Warren Eric · CIK 0001916048 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 45,837

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 stock selling plan adopted on March 27, 2026.

SEC source: 0001933414-26-000118 · wk-form4_1786577585.xml · derivative · entry 3

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 13,024

Underlying: Common Stock · 2,170 shares

Expires 2033-02-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.

F2 · derivative.exercise_date: The stock option vests as to 25% of the total number of shares of Common Stock subject to the option on the first anniversary of the grant date, and as to 1/48th of the total number of shares of Common Stock subject to the option on each monthly anniversary thereafter.

SEC source: 0001933414-26-000118 · wk-form4_1786577585.xml · nonDerivative · entry 2

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 51,384

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.

SEC source: 0001933414-26-000118 · wk-form4_1786577585.xml · nonDerivative · entry 1

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 53,554

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.

SEC source: 0001933414-26-000120 · wk-form4_1786577597.xml · derivative · entry 2

Ferguson James J. III · CIK 0001769041 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 135,000

Underlying: Common Stock · 135,000 shares

Expires 2036-08-10

F2 · derivative.exercise_date: The stock option vests as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter.

SEC source: 0001933414-26-000120 · wk-form4_1786577597.xml · nonDerivative · entry 1

Ferguson James J. III · CIK 0001769041 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 102,400

F1 · shares: Restricted Stock Units (RSUs) are granted to the reporting person for no additional cash consideration, each of which represents a contingent right to receive one share of common stock upon vesting. The RSUs vest in annual installments over a period of four years, with 1/4th of the total shares underlying the RSU vesting on each one-year anniversary of the date of grant.

SEC source: 0001916048-26-000009 · wk-form4_1784846362.xml · derivative · entry 3

Warren Eric · CIK 0001916048 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 245,438

Underlying: Common Stock · 7,438 shares

Expires 2035-04-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 stock selling plan adopted on March 27, 2026.

F3 · derivative.exercise_date: The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter.

SEC source: 0001916048-26-000009 · wk-form4_1784846362.xml · nonDerivative · entry 2

Warren Eric · CIK 0001916048 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 38,400

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 stock selling plan adopted on March 27, 2026.

F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $26.53 to $27.09. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

SEC source: 0001916048-26-000009 · wk-form4_1784846362.xml · nonDerivative · entry 1

Warren Eric · CIK 0001916048 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 45,838

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 stock selling plan adopted on March 27, 2026.

SEC source: 0001672659-26-000036 · wk-form4_1784595624.xml · derivative · entry 3

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,334

Underlying: Common Stock · 416 shares

Expires 2033-03-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.

F2 · derivative.exercise_date: The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter.

SEC source: 0001672659-26-000036 · wk-form4_1784595624.xml · nonDerivative · entry 2

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 51,384

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.

SEC source: 0001672659-26-000036 · wk-form4_1784595624.xml · nonDerivative · entry 1

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 51,800

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.

SEC source: 0001933414-26-000099 · wk-form4_1784163485.xml · nonDerivative · entry 5

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 51,384

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.

F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $26.41 to $27.15. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.

SEC source: 0001933414-26-000099 · wk-form4_1784163485.xml · derivative · entry 8

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,349 shares

Expires 2032-07-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.

F5 · derivative.exercise_date: The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter.

SEC source: 0001933414-26-000099 · wk-form4_1784163485.xml · derivative · entry 7

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 79,167

Underlying: Common Stock · 4,167 shares

Expires 2034-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.

F5 · derivative.exercise_date: The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter.

SEC source: 0001933414-26-000099 · wk-form4_1784163485.xml · derivative · entry 6

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 109,792

Underlying: Common Stock · 3,542 shares

Expires 2035-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.

F4 · derivative.exercise_date: The stock option vests in monthly installments over a period of four years, with 1/48th of the total shares underlying the option vesting each one-month period following the date of grant.

SEC source: 0001933414-26-000099 · wk-form4_1784163485.xml · nonDerivative · entry 4

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 57,733

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.

F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $26.965 to $27.750. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

SEC source: 0001933414-26-000099 · wk-form4_1784163485.xml · nonDerivative · entry 3

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 71,791

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.

SEC source: 0001933414-26-000099 · wk-form4_1784163485.xml · nonDerivative · entry 2

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 65,442

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.

SEC source: 0001933414-26-000099 · wk-form4_1784163485.xml · nonDerivative · entry 1

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 61,275

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.

SEC source: 0001933414-26-000100 · wk-form4_1784163491.xml · nonDerivative · entry 1

Congleton Jon · CIK 0001644975 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 603,621

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on January 28, 2025.

F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $26.80 to $27.58. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

SEC source: 0001672659-26-000033 · wk-form4_1783725320.xml · derivative · entry 3

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 15,194

Underlying: Common Stock · 2,171 shares

Expires 2033-02-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.

F3 · derivative.exercise_date: The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter.

SEC source: 0001672659-26-000033 · wk-form4_1783725320.xml · nonDerivative · entry 2

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 57,733

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.

SEC source: 0001672659-26-000033 · wk-form4_1783725320.xml · nonDerivative · entry 1

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 59,904

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.

F2 · balance_after: This balance includes 638 shares purchased under the Mineralys Therapeutics, Inc. 2023 Employee Stock Purchase Plan that were not previously reported.

SEC source: 0001933414-26-000096 · wk-form4_1782859282.xml · nonDerivative · entry 2

Congleton Jon · CIK 0001644975 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 614,321

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 30, 2025.

F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $26.6450 to $26.8200. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.

SEC source: 0001933414-26-000096 · wk-form4_1782859282.xml · nonDerivative · entry 1

Congleton Jon · CIK 0001644975 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 631,321

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 30, 2025.

F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $25.5600 to $26.5000. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

SEC source: 0001933414-26-000095 · wk-form4_1782859276.xml · derivative · entry 3

Warren Eric · CIK 0001916048 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 252,876

Underlying: Common Stock · 104,124 shares

Expires 2035-04-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 stock selling plan adopted on March 27, 2026.

F3 · derivative.exercise_date: The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter.

SEC source: 0001933414-26-000095 · wk-form4_1782859276.xml · nonDerivative · entry 2

Warren Eric · CIK 0001916048 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 38,400

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 stock selling plan adopted on March 27, 2026.

F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $25.8941 to $25.9100. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

SEC source: 0001933414-26-000095 · wk-form4_1782859276.xml · nonDerivative · entry 1

Warren Eric · CIK 0001916048 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 142,524

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 stock selling plan adopted on March 27, 2026.

SEC source: 0001933414-26-000093 · wk-form4_1781745479.xml · derivative · entry 3

Karydas Daphne · CIK 0001816952 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 38,000

Underlying: Common Stock · 3,000 shares

Expires 2033-09-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 30, 2025.

F2 · derivative.exercise_date: The stock option vests in 36 monthly installments beginning on October 13, 2023.

SEC source: 0001933414-26-000093 · wk-form4_1781745479.xml · nonDerivative · entry 2

Karydas Daphne · CIK 0001816952 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,200

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 30, 2025.

SEC source: 0001933414-26-000093 · wk-form4_1781745479.xml · nonDerivative · entry 1

Karydas Daphne · CIK 0001816952 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 9,200

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 30, 2025.

SEC source: 0001933414-26-000094 · wk-form4_1781745485.xml · derivative · entry 8

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,750

Underlying: Common Stock · 417 shares

Expires 2033-03-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.

F4 · derivative.exercise_date: The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter.

SEC source: 0001933414-26-000094 · wk-form4_1781745485.xml · derivative · entry 7

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 83,334

Underlying: Common Stock · 4,167 shares

Expires 2034-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.

F4 · derivative.exercise_date: The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter.

SEC source: 0001933414-26-000094 · wk-form4_1781745485.xml · nonDerivative · entry 5

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 57,095

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.

SEC source: 0001933414-26-000094 · wk-form4_1781745485.xml · nonDerivative · entry 4

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 61,679

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.

SEC source: 0001933414-26-000094 · wk-form4_1781745485.xml · nonDerivative · entry 3

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 61,262

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.

SEC source: 0001933414-26-000094 · wk-form4_1781745485.xml · derivative · entry 6

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 113,334

Underlying: Common Stock · 3,542 shares

Expires 2035-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.

F3 · derivative.exercise_date: The stock option vests in monthly installments over a period of four years, with 1/48th of the total shares underlying the option vesting each one-month period following the date of grant.

SEC source: 0001933414-26-000094 · wk-form4_1781745485.xml · nonDerivative · entry 2

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 57,095

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.

F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $23.41 to $23.98. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

SEC source: 0001933414-26-000094 · wk-form4_1781745485.xml · nonDerivative · entry 1

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 66,985

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.